MorphoSys (ETR:MOR) Given a €116.00 Price Target by Deutsche Bank Aktiengesellschaft Analysts

MorphoSys (ETR:MOR) has been assigned a €116.00 ($136.47) price objective by equities researchers at Deutsche Bank Aktiengesellschaft in a research report issued on Thursday, Borsen Zeitung reports. The firm presently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s target price suggests a potential upside of 54.96% from the stock’s current price.

A number of other research firms have also recently issued reports on MOR. Barclays set a €90.00 ($105.88) price objective on MorphoSys and gave the company a “neutral” rating in a research report on Tuesday, March 2nd. The Goldman Sachs Group set a €88.00 ($103.53) price objective on MorphoSys and gave the company a “neutral” rating in a research report on Monday, March 22nd. Independent Research set a €95.00 ($111.76) price objective on MorphoSys and gave the company a “buy” rating in a research report on Wednesday, March 17th. Royal Bank of Canada set a €130.00 ($152.94) price objective on MorphoSys and gave the company a “neutral” rating in a research report on Tuesday, March 16th. Finally, Berenberg Bank set a €140.00 ($164.71) price objective on MorphoSys and gave the company a “buy” rating in a research report on Wednesday, March 17th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. MorphoSys has an average rating of “Hold” and a consensus price target of €109.78 ($129.15).

Shares of ETR MOR opened at €74.86 ($88.07) on Thursday. The stock has a 50 day moving average price of €81.06 and a 200 day moving average price of €91.66. MorphoSys has a 52 week low of €71.62 ($84.26) and a 52 week high of €125.20 ($147.29). The company has a debt-to-equity ratio of 51.21, a quick ratio of 5.89 and a current ratio of 6.02. The stock has a market capitalization of $2.45 billion and a PE ratio of 25.20.

About MorphoSys

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia.

Recommended Story: What are different types of coverage ratios?

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.